Nephritis couples oxidative stress with immune dysregulation, demanding therapies that localize to inflamed tissue and actively neutralize reactive oxygen species (ROS). We engineered a mannose-functionalized cerium oxide nanozyme co-loaded with dexamethasone (Man-CeO₂@DEX) to unify CD206-mediated targeting with self-regenerating Ce³⁺/Ce⁴⁺ redox catalysis. In acellular assays, Man-CeO₂@DEX most strongly suppressed •OH, outperforming CeO₂ and free DEX. In LPS-primed cells, Man-CeO₂@DEX lowered IL-1β/IL-6 and enhancing macrophage repolarization. The platform couples receptor-guided cellular enrichment with catalytic, continuous ROS clearance to potentiate local glucocorticoid action while minimizing systemic exposure. These data establish Man-CeO₂@DEX as a translatable strategy for ROS-driven renal inflammation.